Patrick Imesch

Contribution of Chronic Fatigue to Psychosocial Status and Quality of Life in Spanish Women Diagnosed with Endometriosis

Learning endometriosis phenotypes from patient-generated data

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy

Pharmacologic therapies in endometriosis: a systematic review

A view on drug resistance in cancer

Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer

Small Targeted Cytotoxics: Current State and Promises from DNA‐Encoded Chemical Libraries

Encoded libraries of chemically modified peptides

AI in health and medicine

Rethinking mechanisms, diagnosis and management of endometriosis

The JAK/STAT signaling pathway: from bench to clinic

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

Interfering with pH regulation in tumours as a therapeutic strategy

A Highly Functional Synthetic Phage Display Library Containing over 40 Billion Human Antibody Clones

Overall survival after pelvic exenteration for gynecologic malignancy

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Expression is Down-Regulated by Oxidative Stress in Endometriosis and Endometriosis-Associated Ovarian Cancer

Endometriosis: pathogenesis and treatment

Development of therapeutic antibodies for the treatment of diseases

SAHA induces caspase‐independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway

Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation

ROS and the DNA damage response in cancer

Cervical cancer

From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines

Depression, Anxiety, and Correlating Factors in Endometriosis: A Systematic Review and Meta-Analysis

Regulation Mechanisms and Signaling Pathways of Autophagy

Recent insights on the genetics and epigenetics of endometriosis

Combination therapy in combating cancer

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

Foxp3+ Treg cells in humoral immunity

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial

The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer

The Expression of Histone Deacetylase 1, But Not Other Class I Histone Deacetylases, Is Significantly Increased in Endometriosis

Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells

Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells

Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

Does Endometriosis Affect Sexual Activity and Satisfaction of the Man Partner? A Comparison of Partners From Women Diagnosed With Endometriosis and Controls

The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells

Fatigue – a symptom in endometriosis

Maltreatment during childhood: a risk factor for the development of endometriosis?

ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas